GMAB News and Press, Genmab A/S From 08/10/22

Genmab A/S press release ( GMAB ): Q2 GAAP EPS of DKK28.66. Revenue of DKK3.16B (+60.4% Y/Y). Shares +1.4% . On Aug. 08, the company raised its FY22 guidance . For further details see: Genmab A/S GAAP EPS of DKK28.66, revenue of DKK3.16B

Genmab ( GMAB ) improves FY 2022 guidance expects its 2022 revenue to be in the range of DKK 12,000M – 13,000M, an increase to the previous guidance of DKK 11,000M – 12,000M, driven primarily by the continued strong growth of DARZALEX net sales as well as the pos...

Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody ® technology platform to develop novel monospecific antibodies First mono...

Cancer immunotherapy developer Immatics ( NASDAQ: IMTX ) is up 17% in Tuesday afternoon trading on volume that is ( IMTX ) four times higher than the normal daily average. Average volume for the stock is 146,757. As of 230p ET, ~586K shares had traded hands. Th...

Genmab ( GMAB ) said global net sales of Darzalex reported by Johnson & Johnson ( JNJ ) rose 38.6% to $1.99B in Q2. Net trade sales were USD 1.02B in the U.S. and $965M in the rest of the world. Genmab receives royalties on the worldwide net sal...

Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for ...

Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure. Epcoritamab could be Genmab's next blockbuster. The stock is not cheap but increasing in...

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...

Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy Total patient population achieved overall response rate (ORR) of 63 per...

Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond. Genmab has an imposing pipeline of proprietary and partnered programs that should provide additional growth opportunities. Genmab recently publicized...